ACCESS Newswire

RAUDER

7.2.2024 01:20:52 CET | ACCESS Newswire | Press release

Share
2nd Latin American Nicotine and Risk Reduction Forum in Panama

Global Experts Highlighted the Importance of Reduced-Risk Alternatives in the Comprehensive Fight Against Smoking

PANAMA CITY, PANAMA / ACCESSWIRE / February 6, 2024 / Razón Autonomía Derecho A.C, RAUDER, a non-profit civil association that advocates for human rights, personal autonomy, and the free development of personality, organized the "2nd Latin American Nicotine and Risk Reduction Forum: Science, Regulation, and Activism" that took place today in Panama City. The objective was to analyze and discuss the crucial role of reduced-risk alternatives in the fight against tobacco.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
President of RAUDER and directors of organizations of vaping

The forum brought together legislators, experts, doctors, scientists, and activists from across the globe. They emphasized the importance of developing public policies that aim towards harm reduction and respect for human rights, and called for a humane and effective approach, that respects consumers' rights and provides safe, science-based regulated options.

Conversations were around studies and relevant practices from various countries on how alternatives, such as vapor products, can significantly contribute to harm reduction in smoking. Participants emphasized that their prohibition in countries such as Mexico, Brazil and Panama has led to an increase in illegal trade and limits smokers' options to access safer alternatives.

"It is essential to recognize and regulate vapor products as reduced-risk alternatives. Prohibition not only prevents smokers from legal options but drives the black market, and gives easier access to minors besides all the other negative consequences that it implies," explained Rafael Lara Liy, RAUDER's director.

Lara also emphasized the importance of science-based information in enabling consumers to make informed decisions; he stressed the need for all voices to be considered in developing public policies. "Prohibition does not work nor does it solve the problem; the whole of society has the right to participate in shaping public policy. We want to contribute a perspective that also considers consumers' rights and information based on scientific evidence regarding reduced-risk alternatives," he said.

Doctor Marina Hoyo, a forum's panelist, said: "As health professionals, we have a responsibility to stay up to date, analyze, understand, and question the evidence. But we also need to approach our patient care from a position of empathy towards people seeking to improve their health. That's why we must consider alternatives that reduce risks. This is the foundation of a therapeutic bond that aims to truly help the individual and not stigmatize them, but rather try to alleviate their condition."

Contact Information:

Joel Hernandez
PR DIRECTOR
joel@nimbus.mx
+524421244955

Related Files
240206 Press Release RAUDER Forum Panama.pdf

SOURCE: RAUDER

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye